Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Annals of Surgical Oncology|April 28, 2021
Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWGChandrajit P Raut, Dario Callegaro, Rosalba Miceli, et al.
Annals of Surgical Oncology|January 3, 2021
Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG)Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.
Pediatric Blood & Cancer|January 20, 2025
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority TrialRoberto Luksch, Emanuela Palmerini, Giuseppe Maria Milano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC TrialDavid S Moura, Jesus M Lopez-Marti, Iva Benesova, et al.
JAMA Network Open|November 6, 2025
Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical TrialSandro Pasquali, Paola Collini, Cleofe Romagosa, et al.
Cancer Communications (London, England)|March 16, 2026
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma CohortJavier Martin-Broto, Sandra J Strauss, Emanuela Palmerini, et al.
JAMA Network Open|November 6, 2023
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma GroupLorenzo D'Ambrosio, Elena Fumagalli, Tommaso Martino De Pas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer CellsRamona Rotolo, Valeria Leuci, Chiara Donini, et al.
Pageof 15